Zentalis Pharmaceuticals Announces FDA Clearance Of IND Application For ZN-d5 For The Treatment Of Hematologic Malignancies

Zentalis Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental pathways of cancers, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for ZN-d5, an oral selective inhibitor of B-cell lymphoma 2 (BCL-2) initially in development for the treatment of hematologic malignancies.

“The acceptance of this IND, our fourth cleared in only five years, highlights the capability and efficiency of our Integrated Discovery Engine in developing novel oncology therapies,” commented Dr. Anthony Sun, Chairman and Chief Executive Officer at Zentalis Pharmaceuticals. “BCL-2 is as an important mediator in restoring the normal apoptotic process in tumor cells, making this protein a vital target for the treatment of cancer. ZN-d5, a BCL-2 inhibitor, may offer patients with hematologic and epithelial malignancies a differentiated therapy option, both as a monotherapy and in combination with other agents including our oral selective estrogen receptor degrader (SERD), ZN-c5. We are thrilled to explore this candidate’s full potential as we advance toward clinical development.”

–Globe Newswire